Introduction
============

Hepatocellular carcinoma (HCC) ranked as the 5th most frequent cancer and was also one of the lethal cancers, particularly in People\'s Republic of China where liver cancer was the most commonly diagnosed cancer and the most prevalent cause of cancer-related deaths followed by lung, stomach, and esophageal cancers (based on the statistics in 2015) ([@b1-mmr-17-02-2297],[@b2-mmr-17-02-2297]). Because HCC was often diagnosed at an advanced stage, the prognosis of HCC patients was not optimistic ([@b3-mmr-17-02-2297]). Therefore, a better understanding of the pathogenesis of HCC and a novel target for the early screening of HCC might improve the survival of HCC patients ([@b4-mmr-17-02-2297]).

MicroRNAs (miRNAs) are small non-coding RNAs (18--25 nucleotides in length) that regulate the expression of multiple mRNAs at the post-transcriptional level by suppressing the stability and the translation of mRNAs ([@b5-mmr-17-02-2297],[@b6-mmr-17-02-2297]). The aberrant expressions of miRNAs was observed in various human cancers, and extensive studies suggested that these deregulated miRNAs had the capacity to distinguish malignant tumors of liver, breast, lung, pancreas and leukemia from adjacent non-tumorous tissue ([@b7-mmr-17-02-2297]--[@b12-mmr-17-02-2297]). miR-338-3p and miR-338-5p originate from an intron of the gene encoding apoptosis-associated tyrosine kinase (AATK). Both miR-338-3p and miR-338-5p are co-expressed because they enjoyed the same promoter together ([@b13-mmr-17-02-2297]). miR-338 was the prvious ID of miR-338-3p, which had been reported in variety of diseases ([@b13-mmr-17-02-2297]--[@b16-mmr-17-02-2297]). miR-338\* is one of the members of miR-338 family and usually represented as miR-338-5p ([@b17-mmr-17-02-2297]). As a member of the miRNA family, miR-338-5p was reported to be correlated with the carcinogenesis and progression of several human cancers including gastric cancer ([@b18-mmr-17-02-2297]), colorectal cancer ([@b19-mmr-17-02-2297]), and glioblastoma ([@b20-mmr-17-02-2297]). However, there were limited studies on the clinical significance of miR-338-5p in HCC. Chen *et al* reported the overexpression of miR-338-5p in tumor tissues of the liver and preoperative plasma by miRNA array in Asian patients ([@b21-mmr-17-02-2297]). Whether miR-338-5p is indeed a qualified diagnostic biomarker for HCC and the underlying molecular mechanism of miR-338-5p in HCC remained unclarified.

Therefore, this study aimed to investigate the diagnostic significance of miR-338-5p in HCC tissues and the molecular mechanism of miR-338-5p in HCC with a combination of meta-analysis and bioinformatics analysis. Our study confirmed the significance of miR-338-5p for the diagnosis of HCC and might promote the understanding of the molecular mechanism underlying it. The framework of this article was displayed in [Fig. 1](#f1-mmr-17-02-2297){ref-type="fig"}.

Materials and methods
=====================

### The process of study selection

In order to obtain the comprehensive data of the diagnostic value of miR-338-5p in HCC, a thorough search for the related studies was conducted in Gene Expression Omnibus (GEO) dataset and other database including PubMed, Embase, Cochrane, Web of Science, Sinomed, Chinese VIP, Wanfang database and China National Knowledge Infrastructure (CNKI) until December 15, 2016 with the searching strategies: (miR-338 or miRNA-338 or microRNA-338 or miR338 or miRNA338 or microRNA338 or 'miR 338' or 'miRNA 338' or 'microRNA 338') and (malignan\* or cancer or tumor or tumour or neoplas\* OR carcinoma) AND (hepatocellular or liver or hepatic or HCC). Studies that meet the following criteria were eligible for the meta-analysis: i) Studies evaluated the expression of miR-338-5p for the diagnosis of HCC; ii) the disease of the patients were validated with golden standard; iii) the number of cases were reported in the study; and iv) the sensitivity and specificity of the diagnostic test were available directly or indirectly from the study. The exclusion criteria of the studies were as follows: i) The content of the studies were irrelevant with HCC; ii) the subjects of experiment were not human beings; iii) there was no sufficient data for researchers to directly acquire or calculate sensitivity or specificity of the diagnostic test; and iv) studies were classified as review, meta-analysis, case study or conference note. Moreover, data of the diagnostic value of miR-338-5p in HCC was also downloaded from the cancer genome atlas (TCGA) (<https://cancergenome.nih.gov/>).

### Data extraction and statistical analysis

The following information and data were extracted from the included studies: The ID no. of each GSE chip, first author, year of publication, country, experiment type, platform of each GSE chip, sample number for the experiment group and control group, tissue types, true positivity (TP), false positivity (FP), false negativity (FN) and true negativity (TN).

MetaDiSc1.4 and STATA12.0 were applied for all the statistical analysis. To explore expression of miR-338-5p, the continuous outcomes of GEO and TCGA datasets were calculated with standard mean difference (SMD). The sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) of the included studies were pooled with the bivariate meta-analysis model ([@b22-mmr-17-02-2297],[@b23-mmr-17-02-2297]). The summary receiver operator characteristic (SROC) curve was plotted according to the sensitivity and specificity from each study. The area under the SROC curve (AUC) calculated from the SROC reflected the capacity of miR-338-5p to differentiate HCC patients from non-cancer patients accurately. An AUC value of 0.5 or 1.0 represents a poor or perfect diagnostic value, respectively ([@b24-mmr-17-02-2297]). Additionally, Q test and I^2^ statistics were employed to assess the heterogeneity between studies. The random-effects model would be used to pool the results if an I^2^ value was more than 50% with a P-value \<0.10; otherwise, a fixed-effects model would be applied ([@b25-mmr-17-02-2297],[@b26-mmr-17-02-2297]). To identify the source of heterogeneity, the subgroup analysis was conducted based on the number and features of the included studies. With regard to the publication bias, the Deeks\' funnel plot asymmetry test was carried out to detect the publication bias, and P-value \<0.05 was indicative of significance.

### The target genes of miR-338-5p

The potential target genes of miR-338-5p came from three sources: The differentially expressed genes from GEO, TCGA and the predicted genes from 12 online software (miRWalk, MicroT4, miRanda, mirBridge, miRDB, miRMap, miRNAMap, PicTar2, PITA, RNA22, RNAhybrid and TargetScan). We firstly searched Gene Expression Omnibus (GEO) datasets for deregulated target genes of miR-338-5p from the mRNA profiling data of HCC samples on December 15, 2016. All the GSE chips shared the same platform: GPL570 (Affymetrix Human Genome U133 Plus 2.0 Array). After preliminary screening, 54 studies remained for further selection. Among the 54 studies, *Homo sapiens* tissue samples instead of cell lines samples were included for further analysis. Finally, 10 HCC datasets (GSE29721, GSE45436, GSE55092, GSE62232, GSE9843, GSE41804, GSE6764, GSE33006, GSE6222 and GSE19665) comprising 431 HCC samples and 198 control samples were chosen for further analysis. Differentially expressed genes (DEGs) between cancer and normal samples of 10 datasets were acquired via GCBI online tool (<https://www.gcbi.com.cn/gclib/html/index>). Fold-change \>1.5, and a P-value \<0.05 was set as the threshold for the DEGs. Another database containing high-throughput data: TCGA was also searched. Publicly available miRNA-seq and RNA-seq data of liver HCC was downloaded from the TCGA data portal (December 2016, <https://gdc-portal.nci.nih.gov/>). Since the TCGA data were a community resource project, additional approval by an ethics committee of our hospital was not mandatory. And the present study adhered to the TCGA publication guidelines and data access policies. From the downloaded data of 377 HCC samples and 50 normal liver samples. R language package DESeq was subsequently used for the calculation of DEGs (Padj \<0.05 and the absolute log2 fold-change \>1). As for the predicted genes, selection was based on the condition that they were recorded in more than 4 of the 12 prediction software. The selected qualified target genes from the online software and the validated target genes from miRWalk were considered as the potential target genes of miR-338-5p.

### The protein-protein-interaction (PPI) network and validation of target genes

To illustrate the interaction between the targets of miR-338-5p, a PPI network was drawn by Cytoskape v.5.3.0. The nodes and edges represented target genes and the interactions between target genes, respectively. Hub genes were identified according to the value of degrees of each node. Protein expression of hub gene was validated by The Human Protein Atlas (HPA), an immunohistochemisty (IHC) database ([@b27-mmr-17-02-2297]). Each antibody in the database has been used for IHC staining of both normal and HCC tissues.

### The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the target genes

The GO and KEGG pathway analysis were performed by the BiNGO and ClueGO plug-in unit in Cytoscape v.3.5.0 for the functional annotation of the target genes. Three GO terms including biological process (BP), cellular component (CC) and molecular function (MF) were utilized to identify the enrichment of target genes. P-value \<0.05 was significant.

Results
=======

### Eligible studies for the meta-analysis

As shown in [Fig. 2](#f2-mmr-17-02-2297){ref-type="fig"}, the flowchart exhibited the selection and retrieval process of the qualified studies. A total of 69 studies were identified as the initial records, and 30 studies remained after the removal of duplicate records. Then, 14 records were excluded in the preliminary screening of the titles and abstracts of the articles. As a consequence, 16 studies were reviewed in the full text. Among the 16 studies, 14 studies were ineligible due to insufficient data of the diagnostic parameters or duplicate data. Eventually, two studies were enrolled for the meta-analysis. Though two included studies were conducted by the same authors, we failed to validate that the two studies shared the same patient cohorts. Thus, we regard the two studies of Chen *et al* as two different studies ([@b21-mmr-17-02-2297],[@b28-mmr-17-02-2297]).

### Assessment of the diagnostic value and the integrated meta-analysis

To comprehensively evaluate the diagnostic value of miR-338-5p, we supplemented the literature analysis with GEO data and TCGA data. We searched the GEO dataset with the same searching strategies in literature meta-analysis. Finally, a total of eligible 11 GSE chips were included in our meta-analysis ([@b29-mmr-17-02-2297]--[@b38-mmr-17-02-2297]) ([Table I](#tI-mmr-17-02-2297){ref-type="table"}), and the expression level of each study were showed in [Fig. 3](#f3-mmr-17-02-2297){ref-type="fig"}. With the random-effects model, the forest-plot represented that no significant difference expression was observed between HCC tissue and normal tissue. The pooled SMD (0.11, 95% CI: −0.13, 0.34) was showed in [Fig. 4](#f4-mmr-17-02-2297){ref-type="fig"}.

From the chi-square test and I^2^ test, significant heterogeneity existed in all the pooled effects (SE, SP, PLR, NLR and DOR) between studies (All I^2^\>50%; P\<0.05). Therefore, random effects model were employed to estimate the overall SE, SP, PLR, NLR and DOR of all the data. As shown in [Figs. 5](#f5-mmr-17-02-2297){ref-type="fig"}--[9](#f9-mmr-17-02-2297){ref-type="fig"}, the SE, SP, PLR, NLR and DOR of all the studies were 0.51 (95% CI: 0.48--0.54), 0.69 (95% CI: 0.65--0.73), 1.76 (95% CI: 1.17--2.66), 0.64 (95% CI: 0.52--0.80) and 3.17 (95% CI: 1.83--5.47). As for the result of SROC, the AUC value of miR-338-5p was 0.691 ([Fig. 10](#f10-mmr-17-02-2297){ref-type="fig"}). Moreover, the Deeks funnel plot asymmetry test was carried out with Stata 12.0, and no publication bias was detected (P\>0.05) ([Fig. 11](#f11-mmr-17-02-2297){ref-type="fig"}).

Now that significant heterogeneity existed between the studies, the subgroup analysis was performed to seek the potential sources of heterogeneity. In the subgroup of sample types, the heterogeneity decreased substantially in the pooling estimates of NLR (49.2%) and DOR (5.6%) in the group of tissue. The value of SE, SP, PLR and DOR were obviously higher in the plasma group (0.83, 0.74--0.90; 0.86, 0.77--0.93; 14.02, 0.08--2,395.96; 61.30, 3.61--1,040.31) than in the tissue group (0.48, 0.45--0.51; 0.67, 0.63--0.71; 1.51, 1.08--2.11; 2.05, 1.51--2.77) and the value of NLR was notably lower in the plasma group (0.21, 0.11--0.38) than in the tissue group (0.81, 0.71--0.92).

With regard to the subgroup of experiment, the heterogeneity decreased substantially in the pooling estimate of DOR (10.3%) in the microarray group, and declined heterogeneity of SE (0%), PLR (0%) and DOR (0.0%) were also observed in the group of qRT-PCR. The value of SE, SP, PLR and DOR were obviously higher in the qRT-PCR group (0.82, 0.71--0.90; 1.00, 0.94--1.00; 46.23, 6.60--323.68; 254.42, 32.2--2,010.45) than in the microarray group (0.49, 0.46--0.52; 0.66, 0.62--0.70; 1.51, 1.11--2.06; 2.15, 1.56--2.97) and the value of NLR was notably lower in the qRT-PCR group (0.19, 0.08--0.47) than in the microarray group (0.79, 0.69--0.91). This result confirmed that types of sample and experiment were the possible sources of heterogeneity in this study.

### Bioinformatics study of the target genes of miR338-5p

According to the results, a total of 1,698 and 1,798 genes were identified as DEGs targeted by miR-338-5p from TCGA and GEO, respectively. Additionally, a total of 3,610 predicted target genes that appeared in more than four times of the 12 online software were obtained. Taking the intersection of the DEGs from GEO and TCGA as well as the qualified predicted targets genes, we selected 423 genes for the following bioinformatics analyses ([Fig. 12](#f12-mmr-17-02-2297){ref-type="fig"}). The PPI network shown in [Fig. 13](#f13-mmr-17-02-2297){ref-type="fig"} illustrated the interactions between the target genes of miR-338-5p. There were 147 nodes and 248 edges in the network. Hub genes with a degree values of more than 11 including NCOR1, IGF1, FOXO1, FOS, CDCA8, BUB1B, PCNA, ESR1, BIRC5, MYC and CDK1 were emphasized in red while the remaining were colored in green. To verify that these hub genes are targeted by miR-338-5p, we obtained the immunohistochemical staining of several of the hub genes including NCOR1 and FOXO1 in HCC tissues and normal tissues. As shown in [Fig. 14](#f14-mmr-17-02-2297){ref-type="fig"}, NCOR1 and FOXO1 were found to have medium staining and moderate intensity in cytoplasmic/menbranous of normal tissues, while a lower staining and weaker intensity of these genes were observed in HCC tissues.

According to the results of GO analysis in cytoskape, the target genes were found to enrich most significantly in the following biological pathways: response to organic substance, response to chemical stimulus and oxoacid metabolic process. As for cellular component and molecular function, target genes mainly assembled in extracellular region part and binding, respectively ([Table II](#tII-mmr-17-02-2297){ref-type="table"}; [Fig. 15](#f15-mmr-17-02-2297){ref-type="fig"}). Moreover, a total of 5 significant pathways were recorded from the KEGG pathway analysis such as valine, leucine and isoleucine degradation, pathways in cancer and cell cycle ([Table III](#tIII-mmr-17-02-2297){ref-type="table"}; [Fig. 16](#f16-mmr-17-02-2297){ref-type="fig"}) were the most significant.

Discussion
==========

Considerable attention has been attracted to miRNAs as promising diagnostic targets for the early screening of human cancers. Prior to our study, several researches have reported some miRNAs had diagnostic value in HCC. A 3-miRNA panel: miR-92-3p, miR-107, and miR-3126-5p discovered by Zhang *et al* were claimed to distinguish HCC patients in early stage and HCC patients with low-level AFP from their corresponding controls with high accuracy ([@b39-mmr-17-02-2297]). Additionally, some single miRNAs including miR-21 and miR-224 also exhibited prominent diagnostic potential for HCC ([@b40-mmr-17-02-2297],[@b41-mmr-17-02-2297]) and so far, only one study referred to the diagnostic value of miR-338-5p in HCC with the method of miRNA array. Chen *et al* ([@b21-mmr-17-02-2297]) reported a moderate ability of miR-338-5p to differentiate HCC from liver cirrhosis with the AUC of 0.799. Furthermore, an extremely strong diagnostic value of miR-338-5p (AUC=0.909) was observed when diagnosing HCC from healthy controls. Despite some advances has been made in exploring the diagnostic capacity of miRNAs for HCC, the diagnostic significance of miR-338-5p in HCC was indefinite, and the relative molecular mechanism has not been elucidated in these studies; therefore our study was the first one to comprehensively assess the diagnostic value of miR-338-5p in HCC with the data from GEO, TCGA and literature as well as to investigate the underlying molecular mechanism through bioinformatics study.

From the meta-analysis result from our collected literature and the integrated meta-analysis, miR-338-5p may serve as a possible diagnostic target for HCC with fair sensitivity and specificity, which enlightened us that miR-338-5p might play an essential role in the occurrence and progression. Previous studies have pointed out that miR-338-5p exerted a tumor suppressive function in a wide range of cancers. In glioblastoma, miR-338-5p was discovered to inhibit the proliferation, invasion and promote apoptosis by targeting EFEMP1 ([@b42-mmr-17-02-2297]); similarly, miR-338-5p significantly attenuated the malignant potential of gastric cancer cells through regulating BMI1 ([@b13-mmr-17-02-2297]). In contrast, miR-338-5p was increased in both blood and tissue of coloreactal cancer (CRC), and represented high area under ROC curve (AUC) of 0.871. The performance of miR-338-5p indicated that it could be a potential biomarker in CRC ([@b19-mmr-17-02-2297]). A similar trend was observed in CRC compared with HCC. Furthermore, according to the subgroup analysis in the integrated meta-analysis, studies with samples from plasma and the method of qRT-PCR were more precise in diagnosing HCC than studies with the controlled conditions, which hinted that the sample type and experiment type may also influence the accuracy of the diagnosis. Although the overall diagnostic ability of miR-338-5p in HCC was the same, which was reflected by the integrated meta-analysis and the meta-analysis from our literature there were still some differences between them. The sensitivity, specificity, diagnostic odds ratio and the area under SROC of the result from the literature meta-analysis were higher than those from the integrated meta-analysis, especially in the evaluation of sensitivity; miR-338-5p showed a poor sensitivity of only 0.51 in the integrated meta-analysis. This might be attributed to the difference in sample type and experiment type as well as the sources of the data. The integrated meta-analysis included GSE datasets from different platforms and TCGA data based on the literature meta-analysis, the samples of which were different. Moreover, due to the limited number of literature, we failed to trace the heterogeneity by carrying out subgroup analysis for our literature meta-analysis. Expanding the sample size was necessary for a more reliable assessment of the diagnostic value of miR-338-5p in HCC.

The results from meta-analysis only provided a superficial hint that miR-338-5p possessed significant diagnostic capacity in HCC and the molecular mechanism underlying it needed further exploration. Thus, we emphasized on the network and functional analysis of the target genes.

We firstly identified the potential target genes of miR-338-5p and further defined the hub genes from PPI network. The 11 hub genes were assumed to correlate closely with miR-338-5p and play essential roles in the miR-338-5p relevant pathogenesis of HCC. Among the hub genes, CDK1 was important protein for the regulation of cell cycles belonging to the cyclin-dependent kinases family ([@b43-mmr-17-02-2297]). The overexpression of CDK1 was detected in various cancers, and a poor prognosis of renal cell carcinoma patients was associated with the high expression of CDK1 and CDK2 ([@b44-mmr-17-02-2297]--[@b48-mmr-17-02-2297]). We hypothesized that CDK1 deregulated by miR-338-5p might promote the deterioration of HCC by affecting the cell cycle of HCC cells. Apart from CDK1, several hub genes such as MYC, BIRC5, IGF1, NCOR1 and FOXO1 participate in the regulation of a wide range of biological processes including cell proliferation, apoptosis and migration ([@b49-mmr-17-02-2297]--[@b57-mmr-17-02-2297]). These genes were reported to be aberrantly expressed in various cancers ([@b58-mmr-17-02-2297]--[@b62-mmr-17-02-2297]) and they were also involved in the malignant progression of HCC ([@b49-mmr-17-02-2297],[@b50-mmr-17-02-2297],[@b52-mmr-17-02-2297],[@b63-mmr-17-02-2297]). It was conceived that miR-338-5p might interact with these molecules through potential signaling pathways to influence the development of HCC. PCNA, a protein that acted as DNA sliding clamp, was found to engage in DNA duplication and repair with its overexpressed in HCC. Further study was necessary to probe into the association between PCNA and miR-338-5p in HCC. In this study, we analyzed 11 hub genes protein expression by HPA database. The result indicated that the expression of FOXO1 and NCOR1 was downregulated in HCC and most likely regulated by miR-338-5p.

GO enrichment analysis was indicative of the possible functions of the target genes in HCC and the results from three GO terms hinted that the target genes were mainly assembled in response to organic substance. Most of the potential functions of the target genes from the GO analysis were accomplished in signaling pathways. Therefore, it is of great importance to investigate the signaling pathways gathered by the target genes of miR-338-5p. From the results of the KEGG pathway analysis, the most significant ten pathways such as pathways in cancer and cell cycle were closely associated with cancer.

Despite the valuable findings acquired from the meta-analysis and bioinformatics study, there were still some limitations in our study. The sample size of our literature was too small for further analysis to identify heterogeneity, which weakened the reliability of our results. Since the samples are from different types, including tissue and plasma, a bias and sensitivity problems might originate from sample types in analysis. Additionally, we only included studies published in Chinese or English, which might cause bias of selection to the meta-analysis. A plausible way to address these issues is to conduct future studies with larger samples and fewer language restrictions to further verify the diagnostic value of miR-338-5p for HCC.

In conclusion, we anticipated that miR-338-5p may serve as a promising diagnostic marker for HCC and miR-338-5p could affect the development of HCC by targeting certain downstream genes and pathways. The future research will be concentrated on validating the target genes of miR-338-5p and its function in the significant signaling pathways mentioned before.

![The framework of this study. The framework described the idea of this study.](MMR-17-02-2297-g00){#f1-mmr-17-02-2297}

![The flowchart: The detailed process of study selection was recorded in the flowchart. After the preliminary screening and full-text scrutinize, three studies were considered eligible studies for the meta-analysis.](MMR-17-02-2297-g01){#f2-mmr-17-02-2297}

![The expression level of each study from TCGA and GEO. Scatter plots were created to illustrate the expression of miR-338-5p in normal tissues and HCC for each study from TCGA and GEO. \*P\<0.05; \*\*P\<0.01. TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; HCC, hepatocellular carcinoma.](MMR-17-02-2297-g02){#f3-mmr-17-02-2297}

![Forest plot of studies calculating SMD of miR-338-5p expression in HCC group compared with control group. SMD, standard mean difference; HCC, hepatocellular carcinoma.](MMR-17-02-2297-g03){#f4-mmr-17-02-2297}

![The pooled SE of the integrated meta-analysis. The pooled SE of the integrated meta-analysis was 0.51 (95% CI: 0.48--0.54).](MMR-17-02-2297-g04){#f5-mmr-17-02-2297}

![The pooled SP of the integrated meta-analysis. The pooled SP of the integrated meta-analysis was 0.69 (95% CI: 0.65--0.73).](MMR-17-02-2297-g05){#f6-mmr-17-02-2297}

![The pooled PLR of the integrated meta-analysis. The pooled PLR of the integrated meta-analysis was 1.76 (95% CI: 1.17--2.66). PLR, positive likelihood ratio.](MMR-17-02-2297-g06){#f7-mmr-17-02-2297}

![The pooled NLR of the integrated meta-analysis. The pooled NLR of the integrated meta-analysis was 0.64 (95% CI: 0.52--0.80). NLR, negative likelihood ratio.](MMR-17-02-2297-g07){#f8-mmr-17-02-2297}

![The pooled DOR of the integrated meta-analysis. The pooled DOR of the integrated meta-analysis was 3.17 (95% CI: 1.83--5.47). DOR, diagnostic odds ratio.](MMR-17-02-2297-g08){#f9-mmr-17-02-2297}

![The pooled SROC of the integrated meta-analysis. The pooled SROC of the integrated meta-analysis was 0.691. SROC, summary receiver operator characteristic.](MMR-17-02-2297-g09){#f10-mmr-17-02-2297}

![The publication bias. The symmetrical Deeks funnel plot indicated no publication bias.](MMR-17-02-2297-g10){#f11-mmr-17-02-2297}

![The Venn diagram for the target genes of miR-338-5p. Three circles represented the collected target genes from three different sources (blue for TCGA, yellow for GEO and green for the predicted target genes) There were 1,698, 1,798 and 3,610 potential target genes from TCGA, GEO and online software, respectively. A total of 423 genes were obtained after taking the intersection of the three parts. TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus.](MMR-17-02-2297-g11){#f12-mmr-17-02-2297}

![The PPI network of the target genes of miR-338-5p. A total of 147 nodes and 248 edges constituted the network, from which 11 hub genes colored in red were identified according to the value of degrees. PPI, protein-protein-interaction.](MMR-17-02-2297-g12){#f13-mmr-17-02-2297}

![The immunohistochemical staining of NCOR1 and FOXO1 in normal tissues and HCC tissues. According to the immunohistochemical results of these genes in HPA database, NCOR1 and FOXO1 presented medium staining in normal tissues; while a lower staining of these genes were observed in HCC tissues. HCC, hepatocellular carcinoma; HPA, the Human Protein Atlas.](MMR-17-02-2297-g13){#f14-mmr-17-02-2297}

![The GO terms of target genes of miR-338-5p. The circles represented different GO terms of BP, CC and MF. The darker the color of the circles presents, the greater the significance the term indicated. The relationship between different GO terms were symbolized by arrows. GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.](MMR-17-02-2297-g14){#f15-mmr-17-02-2297}

![The network of KEGG pathway analysis. Five large circles in the network represented the corresponding significant pathways from KEGG. Small circles linked by the edges between the large circles symbolized the genes contained in these pathways and the common genes shared by multiple pathways were marked by a combination of colors. KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-17-02-2297-g15){#f16-mmr-17-02-2297}

###### 

Basic information and clinical data of the included studies.

  GEO accession   Author, year                      Public year   Country       Experiment type                     Platform   HCC     Control   Sample type   TP      FP    FN      TN      (Refs.)
  --------------- --------------------------------- ------------- ------------- ----------------------------------- ---------- ------- --------- ------------- ------- ----- ------- ------- -------------------------
  GSE6857         Budhu *et al*, 2008               2008          USA           Non-coding RNA profiling by array   GPL4700    240     241       Tissue          91    62    149     179     ([@b29-mmr-17-02-2297])
  GSE12717        Su *et al*, 2009                  2008          USA           Non-coding RNA profiling by array   GPL7274      10        6     Tissue            7     1       3       5   ([@b30-mmr-17-02-2297])
  GSE22058        Burchard *et al*, 2010            2010          USA           Non-coding RNA profiling by array   GPL10457     96      96      Tissue          36      8     60      88    ([@b31-mmr-17-02-2297])
  GSE40744        Diaz *et al*, 2013                2013          USA           Non-coding RNA profiling by array   GPL14613     26      19      Tissue            8     4     18      26    ([@b32-mmr-17-02-2297])
  GSE50013        Shen *et al*, 2013                2013          USA           Non-coding RNA profiling by array   GPL15497     18      18      Plasma          16    10        2       8   ([@b33-mmr-17-02-2297])
  GSE41874        Morita (unpublished)              2013          Japan         Non-coding RNA profiling by array   GPL7722        6       4     Tissue            4     1       2       3   --
  GSE57555        Murakami *et al*, 2015            2015          Japan         Non-coding RNA profiling by array   GPL16699       5     16      Tissue            4     6       1     10    ([@b34-mmr-17-02-2297])
  GSE74618        Martinez-Quetglas *et al*, 2016   2016          Spain         Non-coding RNA profiling by array   GPL14613   223       20      Tissue        131     10      92      10    ([@b35-mmr-17-02-2297])
  GSE36915        Shih *et al*, 2012                2012          Taiwan        Non-coding RNA profiling by array   GPL8179      68      21      Tissue          37      6     31      15    ([@b36-mmr-17-02-2297])
  GSE39678        Noh *et al*, 2013                 2013          South Korea   Non-coding RNA profiling by array   GPL15852     16        8     Tissue          14      2       2       6   ([@b37-mmr-17-02-2297])
  GSE21362        Sato *et al*, 2011                2011          Japan         Non-coding RNA profiling by array   GPL10312     73      73      Tissue          27    16      46      57    ([@b38-mmr-17-02-2297])
  TCGA                                                                          miRNA-Seq                           Illumina   375       50      Tissue        156       8   218       42    
  Literaure       Chen *et al*, 2015                2015          China         qRT-PCR                                          37      31      Plasma          27      0     10      31    ([@b21-mmr-17-02-2297])
  Literaure       Chen *et al*, 2015                2015          China         qRT-PCR                                          39      25      Plasma          35      4       4     21    ([@b28-mmr-17-02-2297])

TP, true positivity; FP, false positivity; FN, false negativity; TN, true negativity.

###### 

GO functional annotation of the target genes of miR-338-5p from Cytoskape.

  ID           Category                GO term                                                P-value        Count
  ------------ ----------------------- ------------------------------------------------------ -------------- -------
  GO:0006082   GO_Biological process   Organic acid metabolic process                         3.87×10^−9^      37
  GO:0016054   GO_Biological process   Organic acid catabolic process                         6.26×10^−9^      16
  GO:0008152   GO_Biological process   Metabolic process                                      1.29×10^−3^    159
  GO:0009056   GO_Biological process   Catabolic process                                      1.15×10^−1^      28
  GO:0007275   GO_Biological process   Multicellular organismal development                   1.11×10^−6^    102
  GO:0048731   GO_Biological process   System development                                     9.71×10^−8^      91
  GO:0048519   GO_Biological process   Negative regulation of biological process              1.82×10^−5^      72
  GO:0048523   GO_Biological process   Negative regulation of cellular process                3.81×10^−5^      66
  GO:0050789   GO_Biological process   Regulation of biological process                       3.62×10^−4^    176
  GO:0065007   GO_Biological process   Biological regulation                                  6.72×10^−5^    189
  GO:0008150   GO_Biological process   Biological_process                                     1.15×10^−3^    336
  GO:0032501   GO_Biological process   Multicellular organismal process                       1.15×10^−5^    133
  GO:0044237   GO_Biological process   Cellular metabolic process                             6.22×10^−3^    132
  GO:0034641   GO_Biological process   Cellular nitrogen compound metabolic process           2.19×10^−2^      59
  GO:0044238   GO_Biological process   Primary metabolic process                              4.35×10^−3^    140
  GO:0050896   GO_Biological process   Response to stimulus                                   4.59×10^−5^    112
  GO:0009719   GO_Biological process   Response to endogenous stimulus                        3.77×10^−9^      34
  GO:0050794   GO_Biological process   Regulation of cellular process                         9.14×10^−4^    166
  GO:0023052   GO_Biological process   Signaling                                              5.63×10^−5^      99
  GO:0044281   GO_Biological process   Small molecule metabolic process                       3.29×10^−8^      62
  GO:0006519   GO_Biological process   Cellular amino acid and derivative metabolic process   5.92×10^−5^      21
  GO:0043436   GO_Biological process   Oxoacid metabolic process                              2.77×10^−9^      37
  GO:0019752   GO_Biological process   Carboxylic acid metabolic process                      2.77×10^−9^      37
  GO:0009987   GO_Biological process   Cellular process                                       2.40×10^−8^    258
  GO:0046395   GO_Biological process   Carboxylic acid catabolic process                      6.26×10^−9^      16
  GO:0009063   GO_Biological process   Cellular amino acid catabolic process                  2.78×10^−6^      10
  GO:0044248   GO_Biological process   Cellular catabolic process                             3.54×10^−2^      25
  GO:0009725   GO_Biological process   Response to hormone stimulus                           4.39×10^−8^      30
  GO:0048545   GO_Biological process   Response to steroid hormone stimulus                   2.46×10^−6^      18
  GO:0006807   GO_Biological process   Nitrogen compound metabolic process                    2.95×10^−3^      67
  GO:0006520   GO_Biological process   Cellular amino acid metabolic process                  4.99×10^−5^      16
  GO:0009605   GO_Biological process   Response to external stimulus                          1.81×10^−8^      35
  GO:0009308   GO_Biological process   Amine metabolic process                                4.15×10^−6^      25
  GO:0009310   GO_Biological process   Amine catabolic process                                9.50×10^−6^      10
  GO:0032502   GO_Biological process   Developmental process                                  5.43×10^−7^    110
  GO:0048856   GO_Biological process   Anatomical structure development                       8.77×10^−7^      94
  GO:0009653   GO_Biological process   Anatomical structure morphogenesis                     1.19×10^−6^      53
  GO:0042221   GO_Biological process   Response to chemical stimulus                          3.51×10^−10^     70
  GO:0010033   GO_Biological process   Response to organic substance                          4.09×10^−11^     52
  GO:0010646   GO_Biological process   Regulation of cell communication                       1.30×10^−5^      48
  GO:0008283   GO_Biological process   Cell proliferation                                     3.68×10^−6^      26
  GO:0044282   GO_Biological process   Small molecule catabolic process                       2.35×10^−5^      18
  GO:0023046   GO_Biological process   Signaling process                                      8.53×10^−6^      77
  GO:0023060   GO_Biological process   Signal transmission                                    8.53×10^−6^      77
  GO:0042127   GO_Biological process   Regulation of cell proliferation                       1.66×10^−6^      41
  GO:0048513   GO_Biological process   Organ development                                      5.37×10^−8^      74
  GO:0009888   GO_Biological process   Tissue development                                     2.37×10^−8^      42
  GO:0044106   GO_Biological process   Cellular amine metabolic process                       1.70×10^−4^      18
  GO:0032787   GO_Biological process   Monocarboxylic acid metabolic process                  3.81×10^−6^      21
  GO:0007165   GO_Biological process   Signal transduction                                    2.88×10^−6^      71
  GO:0010648   GO_Biological process   Negative regulation of cell communication              3.44×10^−6^      22
  GO:0051239   GO_Biological process   Regulation of multicellular organismal process         1.60×10^−6^      48
  GO:0042180   GO_Biological process   Cellular ketone metabolic process                      5.36×10^−9^      37
  GO:0050793   GO_Biological process   Regulation of developmental process                    1.88×10^−6^      39
  GO:0005515   GO_Molecular function   Protein binding                                        2.06×10^−6^    223
  GO:0003674   GO_Molecular function   Molecular_function                                     4.03×10^−4^    359
  GO:0005488   GO_Molecular function   Binding                                                8.63×10^−8^    316
  GO:0048037   GO_Molecular function   Cofactor binding                                       3.31×10^−6^      19
  GO:0005102   GO_Molecular function   Receptor binding                                       1.45×10^−7^      46
  GO:0005575   GO_Cellular component   Cellular_component                                     1.14×10^−2^    370
  GO:0005615   GO_Cellular component   Extracellular space                                    1.96×10^−8^      42
  GO:0005576   GO_Cellular component   Extracellular region                                   1.10×10^−5^      73
  GO:0044421   GO_Cellular component   Extracellular region part                              3.08×10^−9^      52

GO, Gene Ontology.

###### 

KEGG pathway analysis of the target genes of miR-338-5p from Cytoskape.

  ID           Name                                         Category   Term P-value   Count
  ------------ -------------------------------------------- ---------- -------------- -------
  GO:0000280   Valine, leucine and isoleucine degradation   KEGG       5.1×10^−6^       9
  GO:0005200   Pathways in cancer                           KEGG       9.5×10^−5^     25
  GO:0004110   Cell cycle                                   KEGG       1.4×10^−4^     12
  GO:0000071   Fatty acid degradation                       KEGG       1.7×10^−4^       7
  GO:0000640   Propanoate metabolism                        KEGG       2.0×10^−4^       6

KEGG, Kyoto Encyclopedia of Genes and Genomes.

[^1]: Contributed equally
